Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05576012Phase 1Completed

First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts

Role: collaborator

NCT05307406Phase 1Completed

A First-in-Human Study With XAB05 in Healthy Subjects

Role: collaborator

NCT03577262Early Phase 1Completed

A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density

Role: collaborator

NCT03668314Phase 1Completed

Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects

Role: collaborator

NCT01662726Phase 2Terminated

A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth

Role: collaborator

All 5 trials loaded